Biomarker discovery could lead to urine test for early stage pancreatic cancer
the ONA take:
A three-protein signature that can both identify the most common form of pancreatic cancer at an early stage and distinguish it from chronic pancreatitis has been found by a team of researchers at Barts Cancer Institute, Queen Mary University of London. The discovery could lead to a novel test for screening people at high risk using a urine sample.
Urine samples from patients with pancreatic cancer were found to have higher levels of LYVE1, REG1A, and TFF1, compared with samples from healthy patients; patients with chronic pancreatitis has significantly lower levels of the proteins than those with cancer.
The three proteins were selected for closer examination based on biological information and performance in statistical analysis.
Combined, they form a robust panel that can detect stages I-II pancreatic cancer with over 90% accuracy. Furthermore, using urine, an inert and less complex fluid than blood, is advantageous in that obtaining samples is noninvasive and can be done repeatedly.
The biomarker panel has good specificity and sensitivity. Pancreatic cancer is diagnosed in more than 80% of patients with the disease after it has already spread, significantly reducing eligibility for curative treatment options.
The researchers are hopeful that a simple, inexpensive test can be developed for use in the clinic within the next few years.
A three-protein signature can identify the most common form of pancreatic cancer at an early stage.
- Acupuncture an Effective Alternative Treatment for Cancer-Related Fatigue
- Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma
- Compound in Teas, Peas, Soybeans May Increases Prostate Cancer Risk
- Fertility Preservation in Male Adolescents and Young Adults With Cancer
- Social, Psychiatric Variables Reduce Cognitive Functioning, QoL in HNC
- HPV and Cancer (Fact Sheet)
- Pain Control More Easily Achieved With Nurse-Led Education in Bone Metastases
- Using Nutrition-Based Strategies to Manage Adverse Effects of Cancer
- Palliative Care Associated With Decreased Costs For Patients With Advanced Cancer
- A Case of Immunotherapy-Induced Myocarditis Concomitant to MG in Lung Cancer
- Online Learning Modules Improve Exercise Counseling, But Not Participation
- ASCO Issues Statement Addressing Alcohol and Cancer
- Duloxetine May Improve AI-Associated Joint Pain in Early Stage Breast Cancer
- Axillary Lymph Node Dissection Predictive for Lymphedema in Breast Cancer
- Drug Combination Does Not Extend Glioblastoma Survival
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|